References
- 1. BHATTACHARYYA S, WEI J, TOURTELLOTTE WG, HINCHCLIFF M, GOTTARDI CG, VARGA J. Fibrosis in systemic sclerosis: common and unique pathobiology. Fibrogenesis Tissue Repair. 2012; 5(Suppl 1):S18.
- 2. MAYEUX R. Biomarkers: potential uses and limitations. NeuroRx. 2004; 1(2):182–8.
- 3. FRANTZI M, BHAT A, LATOSINSKA A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014; 3(1):7.
- 4. BĂLĂNESCU P, LĂDARU A, BĂLĂNESCU E, BĂICUŞ C, DAN GA. Systemic sclerosis biomarkers discovered using mass-spectrometry-based proteomics: a systematic review. Biomarkers. 2014; 19(5):345–55.
- 5. MISCHAK H, ALLMAIER G, APWEILER R, ATTWOOD T, BAUMANN M, BENIGNI A, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010; 2(46):46ps42.
- 6. RYU C, WALIA A, ORTIZ V, PERRY C, WOO S, REEVES BC, et al. Bioactive Plasma Mitochondrial DNA is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2020 Jun 30. doi: 10.1002/art. 41418. Epub ahead of print.
- 7. LANDI C, BARGAGLI E, CARLEO A, REFINI RM, BENNETT D, BIANCHI L, et al. Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers. Rheumatology (Oxford). 2019; 58(1):165–178.
- 8. CORALLO C, SANTUCCI A, BERNARDINI G, FIGURA N, LEONCINI R, RIOLO G, et al. Proteomic Investigation of Dermal Fibroblasts Isolated from Affected and Unaffected Skin Samples from Patients with Limited Cutaneous Systemic Sclerosis: 2 Distinct Entities? J Rheumatol. 2017; 44(1):40–48.
- 9. VAN BON L, COSSU M, LOOF A, GOHAR F, WITTKOWSKI H, VONK M, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014; 73(8):1585–9.
- 10. CHAIRTA P, NICOLAOU P, SOKRATOUS K, GALANT C, HOUSSIAU F, OULAS A, et al. Comparative analysis of affected and unaffected areas of systemic sclerosis skin biopsies by high-throughput proteomic approaches. Arthritis Res Ther. 2020; 22(1):107.
- 11. MULLENBROCK S, LIU F, SZAK S, HRONOWSKI X, GAO B, JUHASZ P, et al. Systems Analysis of Transcriptomic and Proteomic Profiles Identifies Novel Regulation of Fibrotic Programs by miRNAs in Pulmonary Fibrosis Fibroblasts. Genes (Basel). 2018; 9(12):588.
- 12. CHAIGNE B, CLARY G, LE GALL M, DUMOITIER N, FERNANDEZ C, LOFEK S, et al. Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ß. Proteomics Clin Appl. 2019; 13(4):e1800069.
- 13. DUMIT VI, KÜTTNER V, KÄPPLER J, PIERA-VELAZQUEZ S, JIMENEZ SA, BRUCKNER-TUDERMAN L, et al. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2014; 134(9):2321–2330.
- 14. SCHILLER HB, MAYR CH, LEUSCHNER G, STRUNZ M, STAAB-WEIJNITZ C, PREISENDÖRFER S, et al. Deep Proteome Profiling Reveals Common Prevalence of MZB1-Positive Plasma B Cells in Human Lung and Skin Fibrosis. Am J Respir Crit Care Med. 2017; 196(10):1298–1310.
- 15. SCHIESS R, WOLLSCHEID B, AEBERSOLD R. Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol. 2009; 3(1):33–44.
- 16. ANDERSON NL, ANDERSON NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002; 1(11):845–67.
- 17. KAYSER C, FRITZLER MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015; 6:167.
- 18. BROWN AJ, SEPURU KM, SAWANT KV, RAJARATHNAM K. Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil-Platelet Crosstalk. Front Immunol. 2017; 8:1248.
- 19. VAN BON L, AFFANDI AJ, BROEN J, CHRISTMANN RB, MARIJNISSEN RJ, STAWSKI L, FARINA GA, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014 Jan 30; 370(5):433–43.
- 20. LUO JY, LIU X, JIANG M, ZHAO HP, ZHAO JJ. Oxidative stress markers in blood in systemic sclerosis: A meta-analysis. Mod Rheumatol. 2017; 27(2):306–314.
- 21. LEPARA Z, LEPARA O, FAJKIĆ A, REBIĆ D, ALIĆ J, SPAHOVIĆ H. Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer. Rom J Intern Med. 2020; 58(3):146–152.
- 22. KUDRYAVTSEVA AV, KRASNOV GS, DMITRIEV AA, ALEKSEEV BY, KARDYMON OL, SADRITDINOVA AF, et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget. 2016 Jul 19; 7(29):44879–44905.
- 23. GOLDFARB AH, GARTEN RS, WALLER J, LABBAN JD. Day to Day Variability and Reliability of Blood Oxidative Stress Markers within a Four-Week Period in Healthy Young Men. J Biomark. 2014; 2014:248313.
- 24. FAN X, CUI L, ZENG Y, SONG W, GAUR U, YANG M. 14-3-3 Proteins Are on the Crossroads of Cancer, Aging, and Age-Related Neurodegenerative Disease. Int J Mol Sci. 2019; 20(14):3518.
- 25. YANG L, ZHANG S, WANG G. Keratin 17 in disease pathogenesis: from cancer to dermatoses. J Pathol. 2019; 247(2):158–165.
- 26. BALANESCU P, LADARU A, BALANESCU E, POMPILIAN V, GOLOGANU D, CARAIOLA S, et al. Circulating Reticulocalbin 1 and Reticulocalbin 3 in Systemic Sclerosis Patients: Results of a Case Control Study. Clin Lab. 2016; 62(6):1109–16.